ZEVRA THERAPEUTICS, INC.
Company Stats
- Market Cap
- $651.4M
- as of Sep 30, 2026
- Enterprise Value
- $652.6M
- Shares Outstanding
- 59.4M
- Free Float
- 91.0%
Income Statement
- Revenue
- $106.5M
- Operating Income
- -$62.9M
- Net Income
- $83.2M
- EBITDA
- -$58.9M
- FCF Margin, 3Y Avg
- -140.2%
- FCF Margin, Worst Year
- -295.0%
Cash Flow
- Free Cash Flow
- -$2.4M
- FCF Yield
- -0.4%
- Owner FCF Yield
- -2.3%
Balance Sheet
- Cash & Equivalents
- $62.4M
- Total Debt
- $63.6M
- Net Debt
- $1.2M
Returns & Capital
- SBC, 3Y Avg
- $11.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $106.5M | -$2.4M | -2.3% |
| FY2024 | $23.6M | -$69.7M | -295.0% |
| FY2023 | $27.5M | -$33.8M | -123.2% |
| FY2022 | $10.2M | -$18.8M | -185.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back